Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 733-739

  Lin, Peng Chan ^a   Lin, Yih Jyh ^b   Lee, Chung Ta ^b   Liu, Hsiao Sheng ^b,c   Lee, Jenq Chang ^b  

^a Institute of Clinical Medicine   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; COX 2; Tumorigenesis

Indexed keywords

CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DISEASE FREE SURVIVAL; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84880430636     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1426     Document Type: Article

References (27)

1. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
2. Bruce WR, Wolever TM and Giacca A: Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer 37: 19-26, 2000.
3. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
4. Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003.
5. Mariani F, Sena P, Marzona L, Riccio M, Fano R, Manni P, et al: Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Lett 279: 221-229, 2009.
6. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF and Powell DW: Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 10: 5870-5879, 2004.
7. Hawcroft G, Ko CW and Hull MA: Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 26: 3006-3019, 2007.
8. Sun Y, Tang XM, Half E, Kuo MT and Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62: 6323-6328, 2002.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
10. Levy BD, Clish CB, Schmidt B, Gronert K and Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612-619, 2001.
11. Charalambous MP, Lightfoot T, Speirs V, Horgan K and Gooderham NJ: Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer 101: 106-115, 2009.
12. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
13. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18: 7908-7916, 1999.
14. Zhang M, Deng CS, Zheng JJ and Xia J: Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27: 1071-1077, 2006.
15. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, et al: Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56: 1557-1563, 2007.
16. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1999.
17. Kohno H, Suzuki R, Sugie S and Tanaka T: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5: 46, 2005.
18. Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H and Kuniyasu H: Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 51: 520-527, 2007.
19. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge B, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998.
20. Tseng YS, Tzeng CC, Huang CY, Chen PH, Chiu AW, Hsu PY, Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area in bladder cancer. Cancer Lett 241: 93-101, 2006.
21. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D and Chow NH: Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20: 1544-1550, 2002.
22. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, et al: Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63: 1748-1751, 2003.
23. DuBois RN, Shao J, Tsujii M, Sheng H and Beauchamp RD: G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56: 733-737, 1996.
24. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, et al: PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132: 76-84, 2006.
25. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, et al: Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58: 5473-5477, 1998.
26. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM and Shureiqi I: Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25: 1225-1241, 2006.
27. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL and Lazar MA: The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19: 49-53, 1998.